Enhancing MR capabilities and strengthening scientific information activities
First written in FY2017. 4 of 8 entries say "Restated". Latest entry: FY2023.
No other company in this theme has enough history to compare yet.
- FY2023AdvancedAnnual report
「In this business, based on compliance with the promotional code, the Company further enhanced the information-provision activities of its MRs (medical representatives), including digital marketing, with the aim of maximizing product value.」
The Company explicitly incorporated digital marketing into measures to enhance MR activities and is working to maximize product value. - FY2020AdvancedAnnual report
「In this business, based on compliance with the promotional code, the Company worked to improve the capabilities of its MRs (medical representatives) and further enhance information-provision activities for medical institutions, including through the establishment of a Digital Marketing Office.」
In addition to the previous focus on improving MR capabilities and academic information activities, the Company implemented a specific organizational measure by establishing a Digital Marketing Office. - FY2019RestatedAnnual report
「In this business, based on compliance with the promotional code, the Company worked to improve the capabilities of its MRs (medical representatives) and further enhance academic information activities for medical institutions.」
The Company continues to pursue compliance with the promotional code, improvement of MR capabilities and enhancement of academic information activities. - FY2019-Q3RestatedAnnual report
「The Company also began joint promotion of Infliximab BS for intravenous infusion 100 mg “Nichi-Iko” in November 2017 and is working to enhance its product lineup in the gastrointestinal field.」
The Company continues to enhance its product lineup in the gastrointestinal field through joint promotion of Infliximab BS. - FY2019-Q2RestatedAnnual report
「The Company also began joint promotion of Infliximab BS for intravenous infusion 100 mg “Nichi-Iko” in November 2017 and is working to enhance its product lineup in the gastrointestinal field.」
The Company continues to enhance its product lineup in the gastrointestinal field through joint promotion of Infliximab BS. - FY2019-Q1RestatedAnnual report
「The Company also began joint promotion of Infliximab BS for intravenous infusion 100 mg “Nichi-Iko” in November 2017 and is working to enhance its product lineup in the gastrointestinal field.」
The Company continues its information-provision and sales activities in the gastrointestinal field through joint promotion of Infliximab BS. - FY2018ReframedAnnual report
「In Japan, the Company is rebuilding its organization to promote efficient and effective MR activities. It will also make full use of the joint promotion with 日医工株式会社 for Zentacort, which became available for long-term prescriptions following the lifting of the treatment-period restriction, and Infliximab BS for intravenous infusion 100 mg “Nichi-Iko,” with the aim of expanding market share in the inflammatory bowel disease field, including Asacol.」
For MR activities, the Company specified a shift in focus from the previous emphasis on improving capabilities and academic information activities to rebuilding an efficient and effective activity structure and making use of product initiatives. - FY2017First statedAnnual report
「Based on compliance with the promotional code, the Company worked to improve the capabilities of its MRs (medical representatives) and further enhance its academic information activities.」
For sales and information-provision activities in the prescription pharmaceutical business, the Company identified compliance with the promotional code, MR training and academic information activities as measures.